Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide.

It has been known for many years that immune system alterations occur in Parkinson's disease (PD). Changes in lymphocyte populations in cerebrospinal fluid and blood, immunoglobulin synthesis, and cytokine and acute phase protein production have been observed in patients with PD. In this regard, PD patients exhibit a lower frequency of infections and cancer, suggesting that immune system stimulation may occur. This hypothesis is further supported by the observation of T-cell activation leading to the production of interferon gamma in PD. As in other CNS degenerative diseases, in damaged regions in the brains of PD patients, there is evidence of inflammation, characterized by glial reaction (especially microglia), as well as increased expression of HLA-DR antigens, cytokines, and components of complement. These observations suggest that immune system mechanisms are involved in the pathogenesis of neuronal damage in PD. The cellular mechanisms of primary injury in PD have not been clarified, however, but it is likely that mitochondrial mutations, oxidative stress and apoptosis play a role. Furthermore, inflammation initiated by neuronal damage in the striatum and the substantia nigra in PD may aggravate the course of the disease. These observations suggest that treatment with anti-inflammatory drugs may act to slow progression of PD.

[1]  F. Cunha,et al.  Interleukin‐8 as a mediator of sympathetic pain , 1991, British journal of pharmacology.

[2]  I. Mefford,et al.  Cytokine-induced activation of the neuroendocrine stress axis persists in endotoxin-tolerant mice , 1991, Brain Research.

[3]  G. Fricchione,et al.  The immune-neuro-link and the macrophage: Postcardiotomy delirium, HIV-associated dementia and psychiatry , 1994, Progress in Neurobiology.

[4]  Jellinger Ka Neurodegenerative disorders with extrapyramidal features--a neuropathological overview. , 1995 .

[5]  C. Brosnan,et al.  Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. , 1991, Journal of Immunology.

[6]  M. Ebadi,et al.  Ubiquinone (Coenzyme Q10) and Mitochondria in Oxidative Stress of Parkinson’s Disease , 2001, Neurosignals.

[7]  T. Bilfinger,et al.  Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. , 1998, Journal of cardiovascular pharmacology.

[8]  S. Mariotto,et al.  Inhibition by sodium nitroprusside of the expression of inducible nitric oxide synthase in rat neutrophils , 1995, British journal of pharmacology.

[9]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[10]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[11]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[12]  H. Nishino,et al.  GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons , 2001, Brain Research.

[13]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[14]  S. Imaoka,et al.  Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. , 1999, Journal of hepatology.

[15]  A. Członkowska,et al.  Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Immunopharmacology.

[16]  A. Członkowska,et al.  [3H]Spiperone binding to lymphocyte in extrapyramidal disease and in aging , 1987, Brain, Behavior, and Immunity.

[17]  Irun R. Cohen,et al.  Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy , 1999, Nature Medicine.

[18]  J. Stamler,et al.  Posttranslational Modification of Glyceraldehyde-3-phosphate Dehydrogenase by S-Nitrosylation and Subsequent NADH Attachment (*) , 1996, The Journal of Biological Chemistry.

[19]  P. Kubes,et al.  Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. , 1994, Circulation research.

[20]  A. Minajeva,et al.  Nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase , 1999, FEBS letters.

[21]  Joseph E Parisi,et al.  Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. , 2002, Archives of neurology.

[22]  M. Blobner,et al.  Inhibition of nitric oxide synthesis improves detoxication in inflammatory liver dysfunction in vivo. , 1997, The American journal of physiology.

[23]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Chrousos,et al.  The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. , 1992, JAMA.

[25]  M. Marletta,et al.  Guanylate cyclase and the .NO/cGMP signaling pathway. , 1999, Biochimica et biophysica acta.

[26]  B. Kalyanaraman,et al.  Nitric oxide and lipid peroxidation. , 1999, Biochimica et biophysica acta.

[27]  B. Liu,et al.  Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[28]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[29]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[30]  S. Moncada,et al.  The Discovery of Nitric Oxide as the Endogenous Nitrovasodilator , 1988, Hypertension.

[31]  A. Rajput,et al.  Is levodopa toxic to human substantia nigra? , 1997, Movement disorders : official journal of the Movement Disorder Society.

[32]  P. Kubes,et al.  Nitric oxide syni hesis inhibition induces leukocyte adhesion via superoxid and mast cells , 2004 .

[33]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[34]  G. Stefano,et al.  HIV gp120 associated neurological deficits: a potential role for nitric oxide and other signal molecules , 1993 .

[35]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[36]  G. Brown,et al.  Reversible binding and inhibition of catalase by nitric oxide. , 1995, European journal of biochemistry.

[37]  T. Bergman,et al.  S-thiolation of human endothelial cell glyceraldehyde-3-phosphate dehydrogenase after hydrogen peroxide treatment. , 1994, European journal of biochemistry.

[38]  I. Mizuta,et al.  Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease , 2000, Neuroscience Letters.

[39]  D. Heistad,et al.  Regulation of the cerebral circulation: role of endothelium and potassium channels. , 1998, Physiological reviews.

[40]  S. Snyder,et al.  Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Schapira Neuroprotection and dopamine agonists , 2002, Neurology.

[42]  S. Mohand-Said,et al.  Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.

[43]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[44]  T. Bilfinger,et al.  Human monocyte adhesion is modulated by endothelin B receptor-coupled nitric oxide release. , 1997, Journal of immunology.

[45]  G. Burnstock,et al.  Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? , 1996, Biochemical and biophysical research communications.

[46]  G. Stefano,et al.  Rebound from Nitric Oxide Inhibition Triggers Enhanced Monocyte Activation and Chemotaxis1 , 2000, The Journal of Immunology.

[47]  F. Hefti,et al.  The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth FACTOR-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture , 1993, Neuroscience.

[48]  A. Członkowska,et al.  Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. , 2002, International immunopharmacology.

[49]  H. Neumann,et al.  Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. , 2001, The American journal of pathology.

[50]  P. Lapchak A role for interleukin‐2 in the regulation of striatal dopaminergic function , 1992, Neuroreport.

[51]  F. Murad Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? , 1998, Recent progress in hormone research.

[52]  C. Elger,et al.  Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis , 2002, Annals of neurology.

[53]  G. Fricchione,et al.  Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. , 1996, Journal of immunology.

[54]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[55]  H. Przuntek,et al.  Selegiline as immunostimulant--a novel mechanism of action? , 1998, Journal of neural transmission. Supplementum.

[56]  T. Hintze,et al.  Nitric oxide. An important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. , 1995, Circulation.

[57]  B. Brüne,et al.  Nitric Oxide-induced S-Glutathionylation and Inactivation of Glyceraldehyde-3-phosphate Dehydrogenase* , 1999, The Journal of Biological Chemistry.

[58]  W. Hickey,et al.  Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. , 1988, Science.

[59]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[60]  X. Xu,et al.  Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney. , 1998, Circulation research.

[61]  M. Graeber,et al.  Parkinson disease: analysis of mitochondrial DNA in monozygotic twins , 2000, Neurogenetics.

[62]  T. Bilfinger,et al.  Basal nitric oxide limits immune, nervous and cardiovascular excitation: human endothelia express a mu opiate receptor , 2000, Progress in Neurobiology.

[63]  K. Tieu,et al.  Inhibition of 6-hydroxydopamine-induced p53 expression and survival of neuroblastoma cells following interaction with astrocytes , 2001, Neuroscience.

[64]  S. Moncada,et al.  Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide , 1994, FEBS letters.

[65]  M. Graeber,et al.  Identity of ED2‐positive perivascular cells in rat brain , 1989, Journal of neuroscience research.

[66]  G. Zhao,et al.  Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. , 1994, Circulation research.

[67]  L. Deecke,et al.  Amantadine in Parkinson's disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies , 2001, Experimental Gerontology.

[68]  N. Rothwell,et al.  Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  M. Masana,et al.  Indomethacin prevents increased catecholamine turnover in rat brain following systemic endotoxin challenge , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[70]  D. Palazzolo,et al.  Interleukin-1 stimulates catecholamine release from the hypothalamus. , 1990, Life sciences.

[71]  G. Defazio,et al.  Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture , 1994, Brain Research.

[72]  V. Perry,et al.  Macrophages and the nervous system. , 1994, International review of cytology.

[73]  R. Kaji,et al.  Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease , 2001, Neuroscience Letters.

[74]  P. Mcgeer,et al.  Inflammation in Parkinson's disease. , 2001, Advances in neurology.

[75]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[76]  G. Fricchione,et al.  Opioid and Opiate Immunoregulatory Processes. , 2017, Critical reviews in immunology.

[77]  A. Fontana,et al.  Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. , 1982, Journal of immunology.

[78]  J. Balligand,et al.  Reversible S-nitrosation of creatine kinase by nitric oxide in adult rat ventricular myocytes. , 1998, Journal of molecular and cellular cardiology.

[79]  I. Ziv,et al.  Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity? , 1998, Movement disorders : official journal of the Movement Disorder Society.

[80]  D. Wink,et al.  Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. , 1998, Free radical biology & medicine.

[81]  H. Magazine,et al.  Thrombin receptor activation inhibits monocyte spreading by induction of ET(B) receptor-coupled nitric oxide release. , 1998, Journal of immunology.

[82]  A. Członkowska,et al.  MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. , 1999, Acta neurobiologiae experimentalis.

[83]  I. Ziv,et al.  Prevention of Dopamine-Induced Cell Death by Thiol Antioxidants: Possible Implications for Treatment of Parkinson's Disease , 1996, Experimental Neurology.

[84]  T. Dawson,et al.  Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[85]  H. Hatanaka,et al.  Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures , 1991, Neuroscience.

[86]  J. C. Torre,et al.  Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide , 2000, Brain Research Reviews.

[87]  A. Dahlström,et al.  Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. , 1990, Journal of neural transmission. Supplementum.

[88]  P. Riederer,et al.  Brain β2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease , 1995 .

[89]  B. Brüne,et al.  Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. , 1992, The Journal of biological chemistry.

[90]  G. Stefano,et al.  Tonal nitric oxide and health: anti-bacterial and -viral actions and implications for HIV. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[91]  H. Kimura,et al.  Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease , 1993, Neurology.

[92]  Wenjie Xie,et al.  Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.

[93]  D. Lefer,et al.  Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. , 1998, Free radical biology & medicine.

[94]  H. Neumann,et al.  Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases , 2002, Trends in Neurosciences.

[95]  A. Dunn Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. , 1992, The Journal of pharmacology and experimental therapeutics.

[96]  A. Hofman,et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.

[97]  O. Abramsky,et al.  Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. , 1978, Perspectives in biology and medicine.

[98]  E. Agranov,et al.  Autoimmune T cells as potential neuroprotective therapy for spinal cord injury , 2000, The Lancet.

[99]  S. Gordon,et al.  Biology of the Macrophage , 1986, Journal of Cell Science.

[100]  C. Richter,et al.  Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. , 1994, Biochemical and biophysical research communications.

[101]  T. Bilfinger,et al.  Effect of prolonged exposure to morphine on responsiveness of human and invertebrate immunocytes to stimulatory molecules , 1995, Journal of Neuroimmunology.

[102]  T. Elizan,et al.  Search for viral particles and virus‐specific products in idiopathic Parkinson disease brain material , 1979, Annals of neurology.

[103]  T. Bilfinger,et al.  Antagonism of LPS and IFN-gamma induced iNOS expression in human atrial endothelia by morphine, anandamide, and estrogen. , 2000, Acta pharmacologica Sinica.

[104]  L. Waite,et al.  Anti-inflammatory drugs protect against Alzheimer disease at low doses. , 2000, Archives of neurology.

[105]  M. Schwartz,et al.  Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. , 2000, Journal of autoimmunity.

[106]  S. Mariotto,et al.  Bacterial Lipopolysaccharide Plus Interferon-γ Elicit a Very Fast Inhibition of a Ca2+-dependent Nitric-oxide Synthase Activity in Human Astrocytoma Cells* , 1997, The Journal of Biological Chemistry.

[107]  P. Carvey,et al.  A Clonal Line of Mesencephalic Progenitor Cells Converted to Dopamine Neurons by Hematopoietic Cytokines: A Source of Cells for Transplantation in Parkinson's Disease , 2001, Experimental Neurology.

[108]  T. Bilfinger,et al.  Macrophage behavior associated with acute and chronic exposure to HIV GP120, morphine and anandamide: endothelial implications. , 1998, International journal of cardiology.

[109]  T. Yamada,et al.  Viral etiology for Parkinson's disease--a possible role of influenza A virus infection. , 1999, Japanese journal of infectious diseases.

[110]  D. Salvemini Regulation of cyclooxygenase enzymes by nitric oxide , 1997, Cellular and Molecular Life Sciences CMLS.

[111]  S. Mariotto,et al.  Rapid Inactivation of NOS-I by Lipopolysaccharide Plus Interferon-γ-induced Tyrosine Phosphorylation* , 1999, The Journal of Biological Chemistry.

[112]  P. Kubes,et al.  Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. , 1993, Circulation research.

[113]  S. Ambrosio,et al.  Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism , 2001, Journal of Neuroimmunology.

[114]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[115]  P. Mcgeer,et al.  Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins , 2004, Acta Neuropathologica.

[116]  V. Kostulas,et al.  Parkinson's disease and immunological abnormalities: increase of HLA‐DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood , 1994, Acta neurologica Scandinavica.

[117]  K. Kristensson Potential role of viruses in neurodegeneration , 1992, Molecular and chemical neuropathology.

[118]  T. Bilfinger,et al.  Antagonism of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. , 1998, Journal of cardiovascular pharmacology.

[119]  W. Hickey,et al.  Leukocyte traffic in the central nervous system: the participants and their roles. , 1999, Seminars in immunology.

[120]  S. Kohbata,et al.  L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice , 1991, Infection and immunity.

[121]  Y. Ganor,et al.  Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates β1 integrin function , 2001, European journal of immunology.

[122]  T. Olsson,et al.  γδ + T cells are increased in patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.

[123]  E. Clarkson,et al.  GDNF reduces apoptosis in dopaminergic neurons in vitro , 1995, Neuroreport.

[124]  T. Esch,et al.  Proinflammation: a common denominator or initiator of different pathophysiological disease processes. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[125]  H. Magazine Detection of endothelial cell-derived nitric oxide: current trends and future directions. , 1995, Advances in neuroimmunology.

[126]  V. Perry,et al.  Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain , 1985, Neuroscience.

[127]  H. Lassmann,et al.  The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis , 2000, Journal of Neuroimmunology.

[128]  A. Członkowska,et al.  Immunological changes in the MPTP-induced Parkinson's disease mouse model , 1993, Journal of Neuroimmunology.

[129]  M. Vila,et al.  The role of glial cells in Parkinson's disease , 2001, Current opinion in neurology.

[130]  C. Cooper,et al.  Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase , 1994, FEBS letters.

[131]  J P Cooke,et al.  Nitric oxide synthase: role in the genesis of vascular disease. , 1997, Annual review of medicine.

[132]  I. Strömberg,et al.  Guidance of dopaminergic neuritic growth by immature astrocytes in organotypic cultures of rat fetal ventral mesencephalon , 2002, The Journal of comparative neurology.

[133]  G. Stefano,et al.  Tonal nitric oxide and health--a free radical and a scavenger of free radicals. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[134]  M. Grisham,et al.  Effect of nitric oxide on hemoprotein-catalyzed oxidative reactions. , 1998, Nitric oxide : biology and chemistry.

[135]  S. Murphy,et al.  Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappaB binding to DNA. , 1997, The Biochemical journal.

[136]  A. Barbeau,et al.  Environmental and genetic factors in the etiology of Parkinson's disease. , 1987, Advances in neurology.

[137]  P. Lapchak,et al.  Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: Selective effects on specific interleukins and interleukin receptors , 1994, Neuroscience.

[138]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[139]  T. Kuroki,et al.  Role of glutathione and nitric oxide in the energy metabolism of rat liver mitochondria , 1997, FEBS letters.

[140]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[141]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[142]  J. Hibbs,et al.  Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.

[143]  M. J. Winn,et al.  Canine hindlimb blood flow and O2 uptake after inhibition of EDRF/NO synthesis. , 1994, Journal of applied physiology.

[144]  G. Stefano Autoimmunovascular regulation: morphine and ancondamide and ancondamide stimulated nitric oxide release , 1998, Journal of Neuroimmunology.

[145]  G. Brown,et al.  Nitric oxide and mitochondrial respiration. , 1999, Biochimica et biophysica acta.

[146]  E. M. Smith,et al.  HIV gp120 alteration of DAMA and IL-1α induced chemotaxic responses in human and invertebrate immunocytes , 1993, Journal of Neuroimmunology.

[147]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[148]  S. Murphy,et al.  Nitric oxide limits transcriptional induction of nitric oxide synthase in CNS glial cells. , 1994, Biochemical and biophysical research communications.

[149]  A. Członkowska,et al.  Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's disease , 1996, Journal of the Neurological Sciences.

[150]  M. Marletta Nitric oxide: biosynthesis and biological significance. , 1989, Trends in biochemical sciences.

[151]  P. Carvey,et al.  Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide , 2002 .

[152]  G. Stefano,et al.  Cyclic nitric oxide release by human granulocytes, and invertebrate ganglia and immunocytes: nano-technological enhancement of amperometric nitric oxide determination. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[153]  M. Graeber,et al.  Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease , 1998, Neurogenetics.

[154]  M. Shichiri,et al.  NO Inhibits Cytokine-Induced iNOS Expression and NF-κB Activation by Interfering With Phosphorylation and Degradation of IκB-α , 1998 .

[155]  R. Bache,et al.  ATP-sensitive K+ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. , 1998, Circulation research.

[156]  S. Milstien,et al.  Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone , 1997, Progress in Neurobiology.

[157]  A. Członkowska,et al.  Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[158]  E. Hansson,et al.  Signaling and gene expression in the neuron–glia unit during brain function and dysfunction: Holger Hydén in memoriam , 2001, Neurochemistry International.

[159]  A. Członkowska,et al.  The immunological status in Parkinson's disease. , 1991, Medical laboratory sciences.

[160]  P. Södersten,et al.  Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease , 1995, Neuroreport.

[161]  C. Caldarera,et al.  Induction of Nitric Oxide Synthase mRNA Expression , 1995, The Journal of Biological Chemistry.

[162]  Solomon H. Snyder,et al.  Nitric oxide, a novel neuronal messenger , 1992, Neuron.

[163]  T. Billiar,et al.  Nitric oxide down-regulates hepatocyte-inducible nitric oxide synthase gene expression. , 1997, Archives of surgery.

[164]  K. Utsumi,et al.  Oxygen-dependent regulation of mitochondrial energy metabolism by nitric oxide. , 1995, Archives of biochemistry and biophysics.

[165]  J. Kanner,et al.  Nitric oxide as an antioxidant. , 1991, Archives of biochemistry and biophysics.

[166]  P. Kubes,et al.  Nitric oxide modulates microvascular permeability. , 1992, The American journal of physiology.